Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Woehrer, A; Hackl, M; Waldhör, T; Weis, S; Pichler, J; Olschowski, A; Buchroithner, J; Maier, H; Stockhammer, G; Thomé, C; Haybaeck, J; Payer, F; von Campe, G; Kiefer, A; Würtz, F; Vince, GH; Sedivy, R; Oberndorfer, S; Marhold, F; Bordihn, K; Stiglbauer, W; Gruber-Mösenbacher, U; Bauer, R; Feichtinger, J; Reiner-Concin, A; Grisold, W; Marosi, C; Preusser, M; Dieckmann, K; Slavc, I; Gatterbauer, B; Widhalm, G; Haberler, C; Hainfellner, JA; Austrian Brain Tumour Registry.
Relative survival of patients with non-malignant central nervous system tumours: a descriptive study by the Austrian Brain Tumour Registry.
Br J Cancer. 2014; 110(2):286-296 Doi: 10.1038/bjc.2013.714 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz

Haybäck Johannes

Payer Franz

von Campe Gord

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Unlike malignant primary central nervous system (CNS) tumours outcome data on non-malignant CNS tumours are scarce. For patients diagnosed from 1996 to 2002 5-year relative survival of only 85.0% has been reported. We investigated this rate in a contemporary patient cohort to update information on survival. We followed a cohort of 3983 cases within the Austrian Brain Tumour Registry. All patients were newly diagnosed from 2005 to 2010 with a histologically confirmed non-malignant CNS tumour. Vital status, cause of death, and population life tables were obtained by 31 December 2011 to calculate relative survival. Overall 5-year relative survival was 96.1% (95% CI 95.1-97.1%), being significantly lower in tumours of borderline (90.2%, 87.2-92.7%) than benign behaviour (97.4%, 96.3-98.3%). Benign tumour survival ranged from 86.8 for neurofibroma to 99.7% for Schwannoma; for borderline tumours survival rates varied from 83.2 for haemangiopericytoma to 98.4% for myxopapillary ependymoma. Cause of death was directly attributed to the CNS tumour in 39.6%, followed by other cancer (20.4%) and cardiovascular disease (15.8%). The overall excess mortality in patients with non-malignant CNS tumours is 5.5%, indicating a significant improvement in survival over the last decade. Still, the remaining adverse impact on survival underpins the importance of systematic registration of these tumours.

Find related publications in this database (using NLM MeSH Indexing)

Adolescent -

Adult -

Adult - epidemiology

Central Nervous System Diseases - mortality

Central Nervous System Diseases - pathology

Female -

Humans -

Male -

Middle Aged -

Registries -

Survival Rate -

Young Adult -

Find related publications in this database (Keywords)

relative survival

CNS tumour

benign behaviour

borderline behaviour

non-malignant

© Med Uni Graz • Impressum